Acp-319

Non-Hodgkins Lymphoma

Acerta Pharma BVPhase 1/2Dormant

CCC

52/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 37/ 100
Competitive Position: 95/ 100

Competitive context

411 Active assets in the Non-Hodgkins Lymphoma cohort.

Asset / Sponsor	Phase	Rating
CYCLOSPORIN A Memorial Sloan Kettering Cancer Center	Phase 3	BBB
PEGASPARGASE Ciusss de L'Est de l'Île de Montréal	Phase 4	BBB
Inno-206 National Cancer Institute (NCI)	Phase 4	BBB
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE Mwanasha Merrill, MD	Phase 3	BBB
Entecavir Fudan University	Phase 4	BBB

View all 50 →

Same molecule, other indications

Acp-319 is also rated in:

B-cell acute lymphoblastic leukemiaDormant

CCC

Indicative ·

50 / 100

plasma cell myelomaDormant

CC

Indicative ·

42 / 100

chronic lymphocytic leukemia/small lymphocytic lymphomaDormant

C

Indicative ·

37 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.